Jessica Wimbush
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica Wimbush has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Eberechukwu Onukwugha
Department of Practice, Sciences, and Health Outcomes Research, University of Maryland School of Pharmacy, Baltimore, MD
11 shared publications - Arif Hussain
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
9 shared publications - Cheryl L. Holt
Department of Behavioral and Community Health, University of Maryland School of Public Health, College Park, Maryland
9 shared publications - David C. Wheeler
Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA
9 shared publications - Derrick A. Butts
Prostate Health Matters, Washington, District of Columbia. 5
9 shared publications - Jessica Yau
Department of Cellular and Molecular Biomedical Science, University of Maryland School of Medicine, Baltimore, Maryland. 3
9 shared publications
Latest Publications
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3)
Concordance Between Claims-Based and Electronic Health Record–Based Comorbidity Measures: An Application Using Linked Data
PURPOSE: The National Cancer Institute Comorbidity Index (NCI-CI) captures patient-level comorbidity burden using diagnosis codes found in administrative claims or electronic health record (EHR) data. However, it is less well understood how claims- and EHR-based comorbidity measures compare. We determined the concordance between the claims-based and EHR-based NCI-CI using a linked data source. MATERIALS AND METHODS: This study used a linkage of tumor registry, EHR, and Medicare claims data. Eligible patients were 65 years and older and were diagnosed and/or received their first course of treatment in 2019-2020. We formed comparison pairs determined by the data source, period relative to the diagnosis date, length of interval for calculating the index, and type of comorbidity index. The primary pair was the 12-month prediagnosis NCI-CI calculated using claims (NCI-CI claims ) and EHR (NCI-CI EHR ) data. We compared pairs using descriptive statistics, correlation coefficients, and histograms. We also identified patient-level factors associated with claims/EHR comorbidity discordance using models of categorical outcomes. RESULTS: The final sample included 1,616 individuals. The median values for NCI-CI claims and NCI-CI EHR were 0.6 (range: 0-4.11) and 0.29 (range: 0-3.06), respectively. We identified moderate correlation (0.49-0.52) between the claims-based and EHR-based comorbidity measures across all comparison pairs. Among individuals with claims-based comorbidities, 32 percent did not report any of those comorbidities based on the EHR data. Older age (eg, age 80+ years) was positively associated with the odds of having a discordant pair. CONCLUSION: In this study, we found moderate correlations between claims-based and EHR-based approaches to NCI comorbidity measures. Mean comorbidity index values were consistently higher using claims data potentially because of more complete capture of health care utilization and diagnoses outside of the hospital system using claims data.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (3)
Concordance Between Claims-Based and Electronic Health Record–Based Comorbidity Measures: An Application Using Linked Data
PURPOSE: The National Cancer Institute Comorbidity Index (NCI-CI) captures patient-level comorbidity burden using diagnosis codes found in administrative claims or electronic health record (EHR) data. However, it is less well understood how claims- and EHR-based comorbidity measures compare. We determined the concordance between the claims-based and EHR-based NCI-CI using a linked data source. MATERIALS AND METHODS: This study used a linkage of tumor registry, EHR, and Medicare claims data. Eligible patients were 65 years and older and were diagnosed and/or received their first course of treatment in 2019-2020. We formed comparison pairs determined by the data source, period relative to the diagnosis date, length of interval for calculating the index, and type of comorbidity index. The primary pair was the 12-month prediagnosis NCI-CI calculated using claims (NCI-CI claims ) and EHR (NCI-CI EHR ) data. We compared pairs using descriptive statistics, correlation coefficients, and histograms. We also identified patient-level factors associated with claims/EHR comorbidity discordance using models of categorical outcomes. RESULTS: The final sample included 1,616 individuals. The median values for NCI-CI claims and NCI-CI EHR were 0.6 (range: 0-4.11) and 0.29 (range: 0-3.06), respectively. We identified moderate correlation (0.49-0.52) between the claims-based and EHR-based comorbidity measures across all comparison pairs. Among individuals with claims-based comorbidities, 32 percent did not report any of those comorbidities based on the EHR data. Older age (eg, age 80+ years) was positively associated with the odds of having a discordant pair. CONCLUSION: In this study, we found moderate correlations between claims-based and EHR-based approaches to NCI comorbidity measures. Mean comorbidity index values were consistently higher using claims data potentially because of more complete capture of health care utilization and diagnoses outside of the hospital system using claims data.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500276
Building Capacity for Research on Cancer, Older Adults, and Under-Represented Populations: Methods and Lessons Learned From the Development of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center-Medicare Database
PURPOSE: This study assessed the feasibility of developing the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC)-Medicare–linked database infrastructure by integrating tumor registry, electronic health records (EHRs), and Medicare administrative claims data. The database was designed to support research identifying determinants of differences in cancer outcomes among patient populations commonly under-represented in clinical trials (based on the US population with the disease) including older adults. METHODS: Patients 65 years and older who were diagnosed and/or received their first course of treatment for a primary tumor at UMGCCC from 2018 to 2021 were included in the database. A two-stage data linkage process was used to merge cancer center tumor registry data with EHR and Medicare claims data. We performed data quality and linkage quality checks. Summary statistics were calculated for patient and tumor characteristics. RESULTS: Of the 3,322 patients identified from the tumor registry, 3,119 patients (94%) were included in the UMGCCC-Medicare database (mean age 73.1 years, 56% male, 31% Black). Lung cancers were the most common (15%) followed by oral cancers (12%) and non-Hodgkin lymphoma (6%). CONCLUSION: The development of the UMGCCC-Medicare database serves as proof of concept for linking real-world data from different sources. The database is a valuable resource for research requiring detailed patient-level data and follow-up that may generate real-world evidence for older adults living in the United States and treated in routine oncology practice.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500276
Building Capacity for Research on Cancer, Older Adults, and Under-Represented Populations: Methods and Lessons Learned From the Development of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center-Medicare Database
PURPOSE: This study assessed the feasibility of developing the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC)-Medicare–linked database infrastructure by integrating tumor registry, electronic health records (EHRs), and Medicare administrative claims data. The database was designed to support research identifying determinants of differences in cancer outcomes among patient populations commonly under-represented in clinical trials (based on the US population with the disease) including older adults. METHODS: Patients 65 years and older who were diagnosed and/or received their first course of treatment for a primary tumor at UMGCCC from 2018 to 2021 were included in the database. A two-stage data linkage process was used to merge cancer center tumor registry data with EHR and Medicare claims data. We performed data quality and linkage quality checks. Summary statistics were calculated for patient and tumor characteristics. RESULTS: Of the 3,322 patients identified from the tumor registry, 3,119 patients (94%) were included in the UMGCCC-Medicare database (mean age 73.1 years, 56% male, 31% Black). Lung cancers were the most common (15%) followed by oral cancers (12%) and non-Hodgkin lymphoma (6%). CONCLUSION: The development of the UMGCCC-Medicare database serves as proof of concept for linking real-world data from different sources. The database is a valuable resource for research requiring detailed patient-level data and follow-up that may generate real-world evidence for older adults living in the United States and treated in routine oncology practice.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S1: Summary of correlations between neighborhood disadvantage metrics.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S1: Summary of correlations between neighborhood disadvantage metrics.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Figure S2: Values of the Neighborhood Deprivation Index (NDI) for participants with residential addresses in Baltimore.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Figure S2: Values of the Neighborhood Deprivation Index (NDI) for participants with residential addresses in Baltimore.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S2: Summary of sensitivity analyses for models by neighborhood metric.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S2: Summary of sensitivity analyses for models by neighborhood metric.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Figure S1: Values of the Area Deprivation Index (ADI) for participants with residential addresses in Maryland.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Figure S1: Values of the Area Deprivation Index (ADI) for participants with residential addresses in Maryland.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Figure S3: Values of the Racial Isolation (RI) index for participants with residential addresses in Maryland.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Figure S3: Values of the Racial Isolation (RI) index for participants with residential addresses in Maryland.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S4: Summary of models by neighborhood metric when only using clinical information to classify prostate tumor aggressiveness.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S4: Summary of models by neighborhood metric when only using clinical information to classify prostate tumor aggressiveness.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S3: Summary of models of neighborhood disadvantage and the likelihood of aggressive prostate cancer by neighborhood metric, additionally adjusting for primary payer at diagnosis.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Supplementary Table S3: Summary of models of neighborhood disadvantage and the likelihood of aggressive prostate cancer by neighborhood metric, additionally adjusting for primary payer at diagnosis.
- Open Access
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Data from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Background:Studies have identified associations between neighborhood disadvantage (ND), which is more likely to affect African American (AA) individuals, and aggressive prostate cancer. Thus, ND may contribute to prostate cancer disparities. However, it is unknown what ND components drive aggressive disease and whether associations vary by race.Methods:We evaluated associations between aggressive prostate cancer and four ND metrics—Area Deprivation Index (ADI), validated Bayesian Neighborhood Deprivation Index (NDI), racial isolation (RI) index, and historical redlining, and whether these factors interacted with race, among men with prostate cancer treated at the University of Maryland Greenebaum Comprehensive Cancer Center (2004–2021).Results:We included 1,458 men (698 European American and 760 AA). AA men were more likely to experience ND. In adjusted models, the ADI, RI, and redlining were significantly associated with aggressive versus nonaggressive prostate cancer overall [ADI, OR for one SD increase = 1.14, 95% confidence interval (CI), 1.00–1.30; RI, OR = 1.27, CI, 1.07–1.51; redlining, OR = 1.77; CI, 1.23–2.56] and among AA men. The NDI was associated with aggressive prostate cancer among AA men (OR = 1.32, 95% credible interval: 1.13–1.57); percent in poverty received the largest importance weight. The ADI (P heterogeneity = 0.002) and NDI (exceedance probability heterogeneity = 98.1%) significantly interacted with race, such that associations were significantly stronger for AA men.Conclusions:We identified novel significant positive associations for racial segregation and historical redlining with aggressive prostate cancer and significant interactions between ND indices and race.Impact:Findings inform specific ND components that are associated with aggressive prostate cancer and suggest the ND effect is stronger for AA men, which has implications for interventions to reduce disparities.
- 2 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Neighborhood Disadvantage and Prostate Tumor Aggressiveness among African American and European American Men
Background:Studies have identified associations between neighborhood disadvantage (ND), which is more likely to affect African American (AA) individuals, and aggressive prostate cancer. Thus, ND may contribute to prostate cancer disparities. However, it is unknown what ND components drive aggressive disease and whether associations vary by race.Methods:We evaluated associations between aggressive prostate cancer and four ND metrics—Area Deprivation Index (ADI), validated Bayesian Neighborhood Deprivation Index (NDI), racial isolation (RI) index, and historical redlining, and whether these factors interacted with race, among men with prostate cancer treated at the University of Maryland Greenebaum Comprehensive Cancer Center (2004–2021).Results:We included 1,458 men (698 European American and 760 AA). AA men were more likely to experience ND. In adjusted models, the ADI, RI, and redlining were significantly associated with aggressive versus nonaggressive prostate cancer overall [ADI, OR for one SD increase = 1.14, 95% confidence interval (CI), 1.00–1.30; RI, OR = 1.27, CI, 1.07–1.51; redlining, OR = 1.77; CI, 1.23–2.56] and among AA men. The NDI was associated with aggressive prostate cancer among AA men (OR = 1.32, 95% credible interval: 1.13–1.57); percent in poverty received the largest importance weight. The ADI (P heterogeneity = 0.002) and NDI (exceedance probability heterogeneity = 98.1%) significantly interacted with race, such that associations were significantly stronger for AA men.Conclusions:We identified novel significant positive associations for racial segregation and historical redlining with aggressive prostate cancer and significant interactions between ND indices and race.Impact:Findings inform specific ND components that are associated with aggressive prostate cancer and suggest the ND effect is stronger for AA men, which has implications for interventions to reduce disparities.